SCHEMBL2287889

SCHEMBL2287889

CCN1c2ccccc2Nc2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSPO P30536 3/20 0.42
ALPL P05186 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
EGFR P00533 1/20 0.39
HDAC3 O15379 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
HDAC4 P56524 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
HDAC1 Q13547 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37
TUBA3E Q6PEY2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102354 0.84 GAA (0.40) GAASMN1; SMN2TSPOALPLMEN1
Trifluoromethanesulfonic Acid SCHEMBL30549287 0.82 GAA (0.42) GAASMN1; SMN2TSPOALPLMEN1
SCHEMBL7164942 0.81 GAA (0.46) GAASMN1; SMN2MEN1KMT2AHDAC3
SCHEMBL21311367 0.80 SMN1; SMN2 (0.38) GAASMN1; SMN2TSPOALPLMEN1
SCHEMBL474136 0.80 POLB (0.46) SMN1; SMN2MEN1KMT2ACNR1GPR55
SCHEMBL29699888 0.80 POLB (0.46) SMN1; SMN2MEN1KMT2ACNR1GPR55
SCHEMBL2877910 0.80
SCHEMBL22710664 0.78 GAA (0.42) GAASMN1; SMN2TSPOALPLMEN1
SCHEMBL8376596 0.78 DRD2 (0.39) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL7207830 0.77 GAA (0.39) GAASMN1; SMN2TSPOALPLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8535511-B2 Methods for electrochemical analysis using matrix compositions with alkylphenazine quaternary salt and a nitrosoaniline ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2013-09-17 US claimed
US-8008037-B2 Matrix composition with alkylphenazine quaternary salt and a nitrosoaniline ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2011-08-30 US claimed
US-5492652-A Dithiopentacene derivatives, their preparation and the use thereof as electron acceptors in charge transfer complexes CIBA-GEIGY CORPORATION (US) 1996-02-20 US claimed
US-5393606-A Electroconductivity CIBA-GEIGY CORPORATION (US) 1995-02-28 US claimed
EP-0588759-A1 Dithiopentacene derivatives, their preparation and their use in charge-transfer complexes CIBA-GEIGY AG (CH) 1994-03-23 EP claimed
EP-0573387-A2 Charge-transfer complex with N-aromatic compounds, their preparation and their use CIBA-GEIGY AG (CH) 1993-12-08 EP claimed
WO-1993014185-A1 CONVENIENT DETERMINATION OF TRACE LEAD IN WHOLE BLOOD AND OTHER FLUIDS ANDCARE, INC. (US) 1993-07-22 WO claimed
CN-117969634-A Electrochemical detection method, device, equipment and medium for blood 三诺生物传感股份有限公司 2024-05-03 CN disclosed
WO-2022109329-A1 TRICYCLIC COMPOUNDS AND RELATED COMPOSITIONS, ZINC ELECTROCHEMICAL CELLS, BATTERIES, METHODS AND SYSTEMS ALIONYX ENERGY SYSTEMS (US) 2022-05-27 WO disclosed
US-11201293-B2 Heterocyclic compound and organic light-emitting device comprising same LG CHEM, LTD. (KR) 2021-12-14 US disclosed
CN-109863153-B Heterocyclic compound and organic light-emitting device comprising same 株式会社LG化学 2021-09-21 CN disclosed
CN-110511913-A Saltant type glucose oxidase and its utilization ARKRAY INC 2019-11-29 CN disclosed
US-20190326517-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2019-10-24 US disclosed
WO-2001032211-A2 CONJUGATE COMPOUNDS FOR TREATING ATHEROMA AND OTHER DISEASES PHARMACYCLICS, INC. (US) 2001-05-10 WO disclosed
US-5492652-A Dithiopentacene derivatives, their preparation and the use thereof as electron acceptors in charge transfer complexes CIBA-GEIGY CORPORATION (US) 1996-02-20 US disclosed
EP-0671393-A1 Monoaminophenazine leuco dyes and photothermographic materials containing same MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-09-13 EP disclosed
US-5436353-A Dithiopentacene derivatives, their preparation and the use thereof as electron acceptors on charge transfer complexes CIBA-GEIGY CORPORATION (US) 1995-07-25 US disclosed
US-5393606-A Electroconductivity CIBA-GEIGY CORPORATION (US) 1995-02-28 US disclosed
EP-0588759-A1 Dithiopentacene derivatives, their preparation and their use in charge-transfer complexes CIBA-GEIGY AG (CH) 1994-03-23 EP disclosed
EP-0573387-A2 Charge-transfer complex with N-aromatic compounds, their preparation and their use CIBA-GEIGY AG (CH) 1993-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11201293-B2 Heterocyclic compound and organic light-emitting device comprising same CYP1A1, CRY1, CYP1B1 GAA 2975/4885SMN1; SMN2 2498/4885TSPO 1602/4885
US-20190326517-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CYP1A1, CRY1, CYP1B1 GAA 2975/4885SMN1; SMN2 2498/4885TSPO 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.